The volatility ratio for the week is 26.33%, and the volatility levels for the past 30 days are at 19.25% for CAMP. The simple moving average for the past 20 days is -49.07% for CAMP’s stock, with a -53.24% simple moving average for the past 200 days.
Is It Worth Investing in CAMP4 Therapeutics Corp (NASDAQ: CAMP) Right Now?
Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CAMP is 3.26M, and currently, short sellers hold a 11.62% ratio of that float. The average trading volume of CAMP on November 26, 2024 was 103.86K shares.
CAMP) stock’s latest price update
The stock price of CAMP4 Therapeutics Corp (NASDAQ: CAMP) has dropped by -17.56 compared to previous close of 5.41. Despite this, the company has seen a fall of -34.60% in its stock price over the last five trading days. globenewswire.com reported 2024-11-21 that – Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M
Analysts’ Opinion of CAMP
Piper Sandler, on the other hand, stated in their research note that they expect to see CAMP reach a price target of $18. The rating they have provided for CAMP stocks is “Overweight” according to the report published on November 05th, 2024.
JP Morgan gave a rating of “Overweight” to CAMP, setting the target price at $23 in the report published on November 05th of the current year.
CAMP Trading at -53.24% from the 50-Day Moving Average
After a stumble in the market that brought CAMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.74% of loss for the given period.
Volatility was left at 19.25%, however, over the last 30 days, the volatility rate increased by 26.33%, as shares sank -59.86% for the moving average over the last 20 days.
During the last 5 trading sessions, CAMP fell by -34.60%, in comparison to the 20-day moving average, which settled at $8.76. In addition, CAMP4 Therapeutics Corp saw -58.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAMP starting from Northpond Ventures II GP, LLC, who purchase 763,636 shares at the price of $11.00 back on Oct 15 ’24. After this action, Northpond Ventures II GP, LLC now owns 763,636 shares of CAMP4 Therapeutics Corp, valued at $8,399,996 using the latest closing price.
AH Equity Partners Bio I, L.L., the 10% Owner of CAMP4 Therapeutics Corp, purchase 727,272 shares at $11.00 during a trade that took place back on Oct 15 ’24, which means that AH Equity Partners Bio I, L.L. is holding 1,579,885 shares at $7,999,992 based on the most recent closing price.
Stock Fundamentals for CAMP
Current profitability levels for the company are sitting at:
- -0.48 for the present operating margin
- 0.36 for the gross margin
The net margin for CAMP4 Therapeutics Corp stands at -0.5. The total capital return value is set at -0.49.
Based on CAMP4 Therapeutics Corp (CAMP), the company’s capital structure generated 1.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.02. The debt to equity ratio resting at -3.26. The interest coverage ratio of the stock is -19.12.
Currently, EBITDA for the company is -8.72 million with net debt to EBITDA at 45.4. When we switch over and look at the enterprise to sales, we see a ratio of 1.58. The receivables turnover for the company is 2.63for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.47.
Conclusion
To put it simply, CAMP4 Therapeutics Corp (CAMP) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
